Too many workers leave the labour market permanently due to health problems, and yet too many people with a disabling condition are denied the opportunity to work. This third report in the OECD series Sickness, Disability and Work explores the possible factors behind this paradox. It looks specifically at the cases of Denmark, Finland, Ireland and the Netherlands, and highlights the roles of institutions and policies. A range
The impact of biotechnologies on medical research is intensifying. Because of new highly performing technologies, we are better able to understand and explore disease and drug mechanisms, which in turn could lead to major changes in the approach of patient care.
In November 2007 the Working Party on Biotechnology established a new Task Force on Biomedicine and Health Innovation. The Task Force was asked to develop a Synthesis Report of the main policy messages that emerged from OECD work related to innovation and health.
English, , 771kb
This paper (Health Working Paper No. 39) describes pharmaceutical pricing and reimbursement policies in Germany, considering them in the broader environment in which they operate, and assesses their impact on the achievement of a number of policy goals.
The focus at the OECD on industrial biotechnology is to identify the potential contribution of biotechnology to sustainable growth and development, and identify and appraise policy options for supply and demand side interventions that can drive efficient transition towards bio-based economy.
Genetics is playing an increasingly important role in health care. New technical advances and information deriving from human genome research are changing health care practices and the economics of healthcare provision.
This report presents the outcome of discussions held by the OECD member countries, together with a number of key partner countries, under the auspices of an expert Task Force established by the OECD Working Party on Biotechnology.
This summary study looks at existing Korean family, health and pension policies from an international perspective and considers them in view of the emerging policy challenges in Korea. It was presented at a policy forum on Low fertility and Ageing Society, in September 2006 in Seoul.
Summarises proceedings of a conference looking at examples of human genetic research databases, how they are established, how they are managed and governed, how they might be commercialised, and what the policy considerations might be.
English, , 849kb
The 2006 edition OECD Biotechnology Statistics includes data for 23 OECD countries and two observer countries, plus China (Shanghai), and takes a major step forward in improving the comparability of biotechnology indicators among countries.